1. Introduction
===============

Prostate-specific antigen (PSA) "gray zone\" in Chinese men (10.1--20 ng/mL) is higher than men of western countries (2.5--10 ng/mL)^\[[@R1]\]^ and the incidence rate of prostate cancer in men of the People\'s Republic of China is 0.000121%.^\[[@R2]\]^ The major problems for men with prostate cancer are overdiagnosis and overtreatment.^\[[@R3]\]^ PSA is widely used for detection of prostate cancer,^\[[@R4]\]^ but it is not useful for detection of prostate cancer in Chinese men.^\[[@R1]\]^ Therefore, currently, the tumors of the prostate are detected by image-guided biopsies and extended-sextant biopsies in PR China.^\[[@R5]\]^ Saturation biopsy is also used for identification of prostate cancer but it has no significant improvement than extended-sextant biopsies for decision-making of prostatectomy.^\[[@R6]\]^ Nowadays, mpMRI (multiparametric magnetic resonance imaging)^\[[@R7]\]^ and transrectal ultrasound (US)-guided biopsies^\[[@R6]\]^ are used for identification of prostate cancer.

Magnetic resonance imaging (MRI) has high resolution, superior pictures, and images obtained are feasible to assign tumor grades than US.^\[[@R8]\]^ However, MRI-guided biopsy procedure is expensive, burdensome, and time-consuming.^\[[@R9]\]^ Moreover, MRI has the ability to detect tumor \>3 mm only.^\[[@R6]\]^ To overcome such impractical issues, MRI/US-fusion biopsy procedure is adopted in the diagnosis of prostate cancer. At present, available studies have proved that MRI/US-guided biopsy is nondominant in the detection of low-risk cancer of the prostate and dominant in the detection of high-risk prostate cancer.^\[[@R5],[@R6],[@R10]\]^ Moreover, MRI/US-guided biopsy has a sensitivity to detect tumor of 2.4 mm^\[[@R6]\]^ and high specificity for prostate cancer. However, low sensitivity for MRI itself may provide false negative results.^\[[@R11]\]^ MRI also has the issue of interobserver variability.^\[[@R12]\]^ Therefore, MRI/US-guided biopsy as the new "criterion standard\" in the detection of prostate cancer is debatable.

The objective of the study was to test the hypothesis that MRI/US fusion-guided biopsy is an accurate diagnostic tool for prostate cancer detection than US-guided biopsy in Chinese men at the level I of evidence^\[[@R13]\]^ without conflict of interest. The secondary endpoint of the study was to compare specificity and sensitivity of targeted biopsies and standard biopsies with whole-mount pathology.

2. Material and methods
=======================

2.1. Reagents
-------------

Hematoxylin, eosin, and formalin were purchased from Mark Specialties, Germany.

2.2. Ethical consideration and consent to participate
-----------------------------------------------------

The study had been registered in research registry ([www.researchregistry.com](http://www.researchregistry.com/)), UID No.: researchregistry3969, dated 15 January 2004. The protocol (UR/CL/17/04, dated 9 January 2004) had been approved by the Heilongjiang Provincial Hospital review board. The study had adhered to Standards of Reporting for MRI-targeted Biopsy Studies (START) Consortium,^\[[@R14]\]^ 1964 Declarations of Helsinki,^\[[@R15]\]^ and the law of China. The work has been reported in line with the STROCSS (Strengthening the Reporting of Cohort Studies in Surgery) criteria.^\[[@R16]\]^ All enrolled patients had been signed an informed consent form before commencement of the study regarding pathology, radiology, anesthesia, surgery, and publication of the finding in all formats (hard and/or electronics) including patients' personal information (image or photograph if any) irrespective of time and language.

2.3. Inclusion criteria
-----------------------

Men who had aged 18 years and above, admitted to Department of Urology of the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China and Heilongjiang Provincial Hospital, Harbin, China from 16 January 2004 to 1 January 2018 with complains of a sudden urge to urinate, dribbling urine after the finish of urinating, difficulties in starting to urinate or emptying urinary bladder, a weak flow when urinating, a feeling that urinary bladder had not emptied properly, pelvic pain, hip pain, back pain, erectile dysfunction, and weight loss were included in the study. Men who had mpMRI that revealed at least 1 lesion in the prostate (as per PI-RADS v1/v2; Table [1](#T1){ref-type="table"}),^\[[@R17]\]^ an elevated level of PSA (the 4 prostate-specific Kallikreins biomarker monoclonal antibody technique tests were performed for the study: total PSA, free PSA, intact PSA, and Human Kallikrein)^\[[@R1]\]^ and an abnormal digital rectal examination (Patients were lied on their side on an examination table, with their knees brought up toward their chest. The evaluator had slid a finger gently into the rectum of patients, Table [2](#T2){ref-type="table"}) were included in the cohort. Total, 998 men who had signed an informed consent form and agreed to radical prostatectomy (if required) were included in the study.

###### 

Criteria selected for Prostate Imaging Reporting and Data System during the study.
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###### 

Observations and conclusion for digital rectal examination.
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The demographic characteristics of the enrolled patients are presented in Table [3](#T3){ref-type="table"}.

###### 

The demographic characteristics of the enrolled patients.
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2.4. Exclusion criteria
-----------------------

Patients who had already diagnosed with prostate cancer contraindicated with mpMRI, and not signed an informed consent form were excluded from the study. Patients who had mpMRI that revealed no lesion in the prostate,^\[[@R17]\]^ normal level of PSA (\<3--5.5 ng/mL as per age, Table [4](#T4){ref-type="table"}),^\[[@R18]\]^ not subjected to MRI/US fusion-guided biopsies, US-guided biopsies, biopsies-related residual hemorrhage, or not agreed for radical prostatectomy (if required) were excluded from the study.

###### 

Normal values of prostate-specific antigen considered for study.
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START Flow diagram of the study is presented in Figure [1](#F1){ref-type="fig"}.

![START Flow diagram of the study. Radical prostatectomy was performed at 44 ± 4 days after mpMRI by a urologist (single surgeon approach). mpMRI = multiparametric magnetic resonance imaging, MRI = magnetic resonance imaging, PSA = prostate-specific antigen, US = ultrasound. Level of Evidence: I.](medi-97-e11962-g005){#F1}

2.5. mpMRI
----------

All enrolled patients were subjected to mpMRI by a 3.0-T MRI (Excite HDXT, GE Healthcare) with 4 sequences--MR spectroscopy, diffusion-weighted imaging, triplanar T2-weighted, and dynamic contrast-enhanced images.^\[[@R19]\]^ Images were acquired with a 16-channel surface coil (NORAS, GmBH, Germany) and an endorectal coil (IN2-989603212881, Imaging Solutions). The images of mpMRI were subjected to evaluation by a team of experts (authors and urologist (s); with minimum three years of experience of diagnostic radiology).^\[[@R20]\]^ Scoring was performed as per PI-RADS v1/v2 guidelines in axial T1W/T2W images, the sagittal T2W images, and diffusion-weighted images.^\[[@R21]\]^

2.6. Biopsies
-------------

Patients whom lesions had identified on mpMRI subjected to MRI/US fusion-guided biopsy (UroNav, Invivo) by a physician followed an inserting of US transducer (CeramTec Suzhou Ltd., Suzhou, PR China) into rectum of men and transrectal US-guided biopsy (SonoScape, GE Healthcare) in the same session by the other physician who was blind for the MRI lesion (s) locations.^\[[@R22]\]^ Men who had faced \>1 MRI/US fusion-guided biopsy sessions, the results of the first successful biopsy session was considered in this analysis. One physician had performed all MRI/US fusion-guided biopsies and the other physician (one person) had performed all transrectal US-guided biopsies. Total of 12 cores (7 from the peripheral zone, 3 from the transitional zone, and 2 from anterior zone) had been taken by US-guided biopsies and 9 cores (5 from the peripheral zone, 3 from the transitional zone, and 1 from anterior zone) had been taken by MRI/US fusion-guided biopsies.

2.7. Beneficial score analysis
------------------------------

Benefits of a diagnostic test were evaluated by decision curve analysis by authors. The net benefit was calculated as per Equation 1:^\[[@R23]\]^ 

If the interpreters disagreed, the final decision on prostatectomy had taken by urologist oneself.

2.8. Radical prostatectomy
--------------------------

A team of experts was concluded for surgeries in men who had diagnosed as prostate cancer (either of biopsies) by a urologist who had at least 3 years of experience (single surgeon approach). Small incisions (2--3 cm) had made in the belly of patients. A urologist had controlled a robotic system of surgical tools from outside the body. A system lets the surgeon used natural wrist movements and a 3-dimensional screen during surgery. The prostate and some tissue (lymph nodes) around it, including the seminal vesicles, were removed.^\[[@R24]\]^ The samples were collected from the resected prostate.

2.9. Whole-mount pathology
--------------------------

Radical prostatectomy specimens were fixed in 40% buffered formalin overnight at room temperature. Cut-off the prostate was made and mounted on a slide (3-mm thickness) with formalin, stained with hematoxylin and eosin, and subjected to detect the risk of cancer (as per TNM staging). One genitourinary pathologist (blinded for the core samples) reviewed all pathologic specimens. The sensitivity and accuracy of biopsy methods were calculated with respect to whole-mounted pathology by authors and urologist (s) (images and specimens were compared).

A specimen of biopsies and whole-mount pathology were evaluated having cancer "yes or no" per lesion only.

A tumor was detected by biopsies but whole-mount pathology examination was failed in the detection of the tumor was considered as a false positive. No prostate cancer was detected by biopsies, but the case clearly had prostate cancer biochemically and developed mpMRI so a prostate was removed and postoperatively tumor was showed in whole-mount pathology examination (Fig. [2](#F2){ref-type="fig"}) was considered as a false-negative.

![Whole-mount prostate tissue section of men (age 62 years, stained with hematoxylin and eosin). Red arrows indicated the tumor lesion.](medi-97-e11962-g007){#F2}

2.10. Cost of diagnosis
-----------------------

Cost for MRI/US fusion-guided biopsy and US-guided biopsy for each individual was reported by calculating the cost of the hospital (stay and operating room charges), pathology (whole-mount pathology), consultant charges (radiologist, urologist, expert team charges), imaging (MRI and US), and pharmacy.^\[[@R25]\]^

2.11. Statistical analysis
--------------------------

InStat (GraphPad, USA) was used for statistical analysis purposes. *χ*^*2*^ test for independence was used for comparisons of biopsies results.^\[[@R5]\]^ DeLong test was used to compare the area under the curves (AUCs) for different biopsies. Two-tailed paired *t* test following Tukey-Kramer Multiple comparisons tests (considering critical value \[*q*\] \>8.243) was used for cost analysis of biopsy methods.^\[[@R26]\]^ Spearman Rank Correlation (considering Spearman Rank Correlation constant \[*r*\] values 0.7213 to 0.73 as significant) was performed between the biopsy results and the subtype of prostate cancer (low, intermediate, high risk). The results were considered significant at 99% of confidence level. Intention-to-treat analysis method was adopted.

3. Results
==========

With respect to whole-mounted pathology, a US-guided biopsy had 0.973 sensitivity and 0.837 accuracies. Whereas MRI/US fusion-guided biopsy had 0.983 sensitivity and 0.91 accuracies. Moreover, combined data of both biopsies had 0.973 sensitivity and 0.917 accuracies (Table [5](#T5){ref-type="table"}, whole-mounted pathology was considered as "criterion standard\"). The area under the curve values for detection of prostate cancer was in the order of MRI/US fusion-guided biopsies procedure \< US-guided biopsies procedure \< combined biopsies procedure \< whole-mounted pathologies.

###### 

Comparisons of diagnostic parameters of different biopsy methods.
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After MRI/US fusion-guided and US-guided biopsies, a panel of surgeons was concluded for radical prostatectomy in 578 men (at 44 ± 4 days after mpMRI). MRI/US fusion-guided biopsy (*P* = .165) and data of combined biopsies (*P* = .182) had the same specificity to whole-mount pathology. However, a US-guided biopsy had not the same specificity to whole-mount pathology (*P* = .0003, Table [6](#T6){ref-type="table"}). The MRI/US fusion-guided biopsy results of the subtype of prostate cancer were correlated with whole-mounted pathology results (*r* = 0.7296). However, the subtype of prostate cancer results of US-guided biopsies was not correlated with whole-mounted pathology results (*r* = 0.7104).

###### 

Results of biopsy methods regarding radical prostatectomy.
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Decision-making zone for radical prostatectomy of different biopsies was in the order of combined data of both biopsies \> MRI/US fusion-guided biopsy \> US-guided biopsy (Fig. [3](#F3){ref-type="fig"}; Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}).

![Decision curve for radical prostatectomy. One physician had performed all MRI/US fusion-guided biopsies and the other physician (one person) had performed all transrectal US-guided biopsies. Level of Evidence: I. Radical prostatectomy was performed at 44 ± 4 days after multiparametric magnetic resonance imaging by a urologist (single surgeon approach). MRI = magnetic resonance imaging, US = ultrasound.](medi-97-e11962-g010){#F3}

###### 

True-positive and false-positive rates of biopsies methods.
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###### 

Net benefits of biopsies methods.
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MRI/US fusion-guided biopsy was expensive for patients than US-guided biopsy (¥6474.85 ± ¥286.15 vs. ¥2359.65 ± ¥75.87, *P* \< .0001, *q* = 757.8, Fig. [4](#F4){ref-type="fig"}).

![Costs of biopsy methods. The bootstrap method used for cost analysis. Two-tailed paired *t* test following Tukey-Kramer Multiple comparisons tests was used for statistical analysis. A *P* value and *q* value for statistical analysis were \<.0001 and 757.8. A *P* \< .01 and *q* \> 8.243 were considered as significant. 6¥  1\$. (No critical values are available for \>1000 sample size, but it was extrapolated manually from that of 1000 available from software InStat, GraphPad).](medi-97-e11962-g013){#F4}

4. Discussion
=============

MRI/US fusion- guided biopsy had high sensitivity, accuracy, specificity, and AUC than a US-guided biopsy and no significant difference for treatment zone between combined biopsies and targeted biopsy methods. Moreover, MRI/US fusion-guided biopsies had detected more numbers of high-risk prostate cancer (Gleason score ≥7, tumor volume \>0.5 mm) than US-guided biopsies (24 vs. 18). These results were in line with available studies.^\[[@R5],[@R6],[@R27]\]^ In respect to the results of the study, a targeted biopsy was a good option for diagnosis of prostate cancer in Chinese men.

Cost of MRI/US fusion-guided biopsy was higher than US-guided biopsy for any individual. These results were in line with available studies.^\[[@R5],[@R6],[@R25]\]^ However, after proper diagnosis, the cost of overdiagnosis and overtreatment,^\[[@R2]\]^ which is a major drawback for any condition of prostate cancer in situ could be overcome. In respect to the value factor of biopsies, the further trial is required to justify the expenditure of MRI/US fusion-guided biopsy, considering total charges from mpMRI to radical prostatectomy including hospital stay and medicines for MRI/US fusion-guided biopsy and US-guided biopsy for the Chinese men.

A human study with level I (Table [9](#T9){ref-type="table"}) of evidence that had followed START checklist revealed that targeted biopsy was successful in detection of high-risk prostate cancer and standard biopsy fusion with targeted biopsy was successful in detection of low-risk prostate cancer. This is because of the higher sensitivity of targeted biopsy.^\[[@R5],[@R6]\]^ However, one additional targeted biopsy after standard biopsy may increase chances of metastasizing.^\[[@R5]\]^ With respect to consideration of risk factor, a prospective cohort study advised urologist to perform targeted biopsy only in case of detection of prostate cancer.

###### 

Level of Evidence.
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The rate of false positive seems very high. Inflammation may interfere with interpretation of MRI by ghost prostate cancer. There are several reasons for false-positive prostate cancer as radiology read, importing/segmentation of images, MRI quality, and biopsy accuracy. One of the strongest reason for false-positive lesion was inflammation of the prostate.^\[[@R28]\]^ A further trial is required to addressed false-positive results combined with novel inflammatory biomarkers.

In limitations of the study, for examples, the risk of the metastasize owing to biopsies and upgrade of the condition of prostate cancer during the course of treatment or follow-up was not evaluated. The possible explanation for not evaluating such parameters was that the study only enrolled patients who had subjected to radical prostatectomy (if prostate cancer was diagnosed) for a prospective cohort. The available studies have enrolled prostate cancer patients, may or may not be operated during the study. Therefore, these studies have evaluated the upgrade of the condition of cancer during follow-up.^\[[@R5],[@R27]\]^ The lack of history of a prostate cancer diagnosis. mpMRI that had revealed no lesion in the prostate of patients were not included in the cohort; however, such patients might have an intermediate or low risk of prostate cancer.^\[[@R29]\]^ The image analysis was performed by authors only; the expert opinions over images by the external examiners had not taken. The study was failed in a finding of the reason behind the diagnosis that why cancer had detected in MRI/US-fusion guided biopsy alone or US-guided biopsy alone. The study was not concentrated on apparent diffusion coefficient (ADC) related to prostate cancers clinical risk. The possible reason is that ADC value used for evaluation of efficacies of chemotherapies not much effective in diagnosis and prognosis of cancer. Large time for study enrollment. Only 2% to 4% of the whole cohort were high-risk disease (Gleason \>3 + 4/4 + 3), these findings were contrasted to literature suggested: the Asian population had more high-risk prostate cancer compared to the white population! The possible justification for the same is at the time of enrollment, all men might be in a benign stage of prostate cancer. The other controversial matter that the study began in 2004 following START criteria. The possible justification for the same is Chinese Department of Health is following START criteria since 1995.

5. Conclusion
=============

A prospective cohort study with level I of evidence concluded that the targeted fusion-guided biopsy had high sensitivity, accuracy, specificity, the area under the curve, and ability to detect the significant prostate cancer than standard biopsy. The study is recommended magnetic resonance/ultrasound fusion-guided biopsy only to a urologist before the decision of prostatectomy.
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